General Information of Drug (ID: DMXW07J)

Drug Name
EDP-239 Drug Info
Synonyms NS5a HCV inhibitors, Enanta
Indication
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMXW07J

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Daclatasvir DMSFK9V Hepatitis C virus infection 1E51.1 Approved [3]
Glecaprevir; pibrentasvir DMF6Z5T Hepatitis C virus infection 1E51.1 Approved [4]
ABT-267 DMNQ869 Hepatitis C virus infection 1E51.1 Phase 3 [5]
MK-8742 DMK301H Hepatitis C virus infection 1E51.1 Phase 3 [6]
Ravidasvir DM1LFUN Hepatitis C 1E51 Phase 2/3 [7]
GS-5885 DMSL3DX Hepatitis C virus infection 1E51.1 Phase 2 [8]
PPI-668 DM4EHVB Hepatitis C virus infection 1E51.1 Phase 2 [2]
ACH-3102 DM0RPY5 Hepatitis C virus infection 1E51.1 Phase 2 [2]
AZD-2836 DMT2FAP Hepatitis C virus infection 1E51.1 Phase 1/2 [9]
BMS-824383 DMPQ5XC Hepatitis C virus infection 1E51.1 Phase 1 [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatitis C virus Non-structural 5A (HCV NS5A) TTCJ2X8 POLG_HCV1 Modulator [2]

References

1 ClinicalTrials.gov (NCT01856426) Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects. U.S. National Institutes of Health.
2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3 2011 Pipeline of Bristol-Myers Squibb.
4 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
5 Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014 Mar 13;57(5):2047-57.
6 Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013 Dec;8(12):1930-40.
7 Clinical pipeline report, company report or official report of Presidio Pharmaceuticals.
8 Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014 Mar 13;57(5):2033-46.
9 TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION. Drugs Future. 2011 September; 36(9): 691-711.